MX349749B - Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico. - Google Patents

Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico.

Info

Publication number
MX349749B
MX349749B MX2013012372A MX2013012372A MX349749B MX 349749 B MX349749 B MX 349749B MX 2013012372 A MX2013012372 A MX 2013012372A MX 2013012372 A MX2013012372 A MX 2013012372A MX 349749 B MX349749 B MX 349749B
Authority
MX
Mexico
Prior art keywords
lysosomal storage
storage diseases
enzyme delivery
intraventricular
delivery
Prior art date
Application number
MX2013012372A
Other languages
English (en)
Inventor
James Dodge
Lamya Shihabuddin
Marco Passini
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX349749B publication Critical patent/MX349749B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención se refiere a las enfermedades de almacenamiento lisosomal pueden ser tratadas de manera exitosa utilizando la administración intraventricular de la enzima, misma que es deficiente etiológicamente en la enfermedad. La administración puede realizarse lentamente para lograr el máximo efecto. Sorprendentemente, los efectos se ven en ambos lados de la barrera sanguíneo-cerebral, haciendo de esto un medio de administración ideal para las enfermedades de almacenamiento lisosomal que afectan tano al cerebro como a los órganos viscerales.
MX2013012372A 2006-01-20 2007-01-22 Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico. MX349749B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76037806P 2006-01-20 2006-01-20
PCT/US2007/001566 WO2007084737A2 (en) 2006-01-20 2007-01-22 Intraventricular enzyme delivery for lysosomal storage diseases

Publications (1)

Publication Number Publication Date
MX349749B true MX349749B (es) 2017-08-10

Family

ID=38288294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012372A MX349749B (es) 2006-01-20 2007-01-22 Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico.

Country Status (19)

Country Link
US (4) US8926967B2 (es)
EP (3) EP3517124A1 (es)
JP (1) JP5681345B2 (es)
CN (1) CN101431960A (es)
AR (2) AR059089A1 (es)
BR (1) BRPI0706699A2 (es)
CA (2) CA2636991C (es)
DK (2) DK1984018T3 (es)
ES (2) ES2716206T3 (es)
HU (1) HUE041840T2 (es)
IL (2) IL192740A (es)
LT (1) LT2666476T (es)
MX (1) MX349749B (es)
PL (2) PL2666476T3 (es)
PT (2) PT1984018E (es)
RU (3) RU2529830C2 (es)
SI (2) SI1984018T1 (es)
TR (1) TR201903855T4 (es)
WO (1) WO2007084737A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX392030B (es) 2006-02-09 2025-03-21 Genzyme Corp Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurológicas
ES2559859T3 (es) 2007-05-16 2016-02-16 The Brigham And Women's Hospital, Inc. Tratamiento de sinucleinopatías
SI2889043T1 (sl) 2008-12-16 2019-08-30 Genzyme Corporation Sintetične vmesne spojine za pripravo konjugatov oligosaharid-protein
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
CN102596232A (zh) 2009-08-28 2012-07-18 西奈山医学院 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
EP2561069B1 (en) 2010-04-23 2017-03-08 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
RU2012154576A (ru) * 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
UA115648C2 (uk) * 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Доставка терапевтичних агентів до цнс
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
BR112012033216B1 (pt) 2010-06-25 2022-10-11 Shire Human Genetic Therapies, Inc Uso de uma formulação estável compreendendo uma proteína arilsulfatase a (asa) e formulação estável para administração intratecal
CN104857504A (zh) 2010-06-25 2015-08-26 夏尔人类遗传性治疗公司 芳基硫酸酯酶a cns递送的方法和组合物
WO2011163651A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
NZ715014A (en) * 2010-09-09 2018-10-26 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
US9682129B2 (en) 2011-12-23 2017-06-20 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
EA039246B1 (ru) * 2012-12-06 2021-12-22 Шир Хьюман Дженетик Терапис, Инк. Способ лечения когнитивных нарушений, связанных с синдромом хантера
US10017581B2 (en) 2013-02-20 2018-07-10 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
IL298675B2 (en) * 2013-06-07 2025-12-01 Genzyme Corp Marker for acid sphingomyelinase disorders and uses thereof
WO2015098989A1 (ja) 2013-12-25 2015-07-02 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
CN106573153A (zh) 2014-02-04 2017-04-19 纽约大学 用于诊断和治疗溶酶体贮积病的颗粒蛋白前体(pgrn)及其衍生物
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA2990565A1 (en) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf and anti-human transferrin receptor antibody
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
US11390656B2 (en) * 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
RU2634113C1 (ru) * 2016-11-18 2017-10-24 Государственное бюджетное учреждение "Академия наук Республики Саха (Якутия)" (ГБУ АН РС(Я)) Способ фиксации головного мозга ископаемого позднеплейстоценового млекопитающего
CN109983031B (zh) 2016-12-26 2022-11-25 Jcr制药股份有限公司 通过血脑屏障的新的抗人转铁蛋白受体抗体
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
WO2020157248A1 (en) 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
RU2723187C1 (ru) * 2019-10-04 2020-06-09 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов HEXA и HEXВ, и фармацевтическая композиция для лечения болезни Тея-Сакса
JP2024506860A (ja) * 2021-02-01 2024-02-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ニーマンピック病ａ型を治療するための組成物及び方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
CA2189067A1 (en) 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
ATE243260T1 (de) 1995-04-17 2003-07-15 Univ Texas Adenovirus helfervirus system
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000503534A (ja) 1996-01-05 2000-03-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスベクターのリコンビナーゼ媒介生成
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
HU227189B1 (en) 1996-09-13 2010-10-28 Transkaryotic Therapies Therapy for alpha-galactosidase a deficiency
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6702945B2 (en) 2000-12-28 2004-03-09 Exxonmobil Research And Engineering Company Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions
US6689756B2 (en) 2001-03-02 2004-02-10 Integra Lifesciences Corporation Treatment of neurological disease
WO2003049654A1 (en) 2001-12-07 2003-06-19 Neuron Therapeutics Protection of neurological tissue by direct cns perfusion cooling
AU2003298749A1 (en) 2002-11-26 2004-06-18 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
JP2006519609A (ja) 2003-03-12 2006-08-31 サマリタン・ファーマシューティカルズ・インコーポレイテッド 神経疾患擬態動物モデル
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005072049A2 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005095955A1 (en) 2004-03-31 2005-10-13 Children, Youth And Women's Health Service Screening for lysosomal storage disease status
WO2005099748A1 (de) * 2004-04-13 2005-10-27 Cilian Ag Rekombinante lysosomale enzyme mit ciliaten-typischem glykosylierungsmuster für die therapie
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
AR059088A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
MX392030B (es) * 2006-02-09 2025-03-21 Genzyme Corp Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurológicas
PT3252161T (pt) * 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal

Also Published As

Publication number Publication date
HUE041840T2 (hu) 2019-05-28
TR201903855T4 (tr) 2019-04-22
PT1984018E (pt) 2014-10-22
EP2666476A1 (en) 2013-11-27
AR059089A1 (es) 2008-03-12
US20190083582A1 (en) 2019-03-21
ES2716206T3 (es) 2019-06-11
ES2526710T3 (es) 2015-01-14
RU2008134120A (ru) 2010-02-27
RU2014129319A (ru) 2016-02-10
US8926967B2 (en) 2015-01-06
EP1984018A4 (en) 2010-07-21
AR109170A2 (es) 2018-11-07
RU2665381C2 (ru) 2018-08-29
IL192740A0 (en) 2009-02-11
US10080783B2 (en) 2018-09-25
CA2636991A1 (en) 2007-07-26
DK1984018T3 (da) 2014-11-03
BRPI0706699A2 (pt) 2011-04-05
US20210228692A1 (en) 2021-07-29
JP5681345B2 (ja) 2015-03-04
DK2666476T3 (en) 2019-04-08
CA2966155A1 (en) 2007-07-26
RU2529830C2 (ru) 2014-09-27
US20150313970A1 (en) 2015-11-05
WO2007084737A3 (en) 2008-10-23
SI1984018T1 (sl) 2014-11-28
RU2018129747A (ru) 2020-02-19
PL2666476T3 (pl) 2019-06-28
PT2666476T (pt) 2019-03-28
PL1984018T3 (pl) 2015-04-30
EP2666476B1 (en) 2018-12-19
JP2009525963A (ja) 2009-07-16
IL250937A0 (en) 2017-04-30
EP3517124A1 (en) 2019-07-31
CA2636991C (en) 2017-07-04
LT2666476T (lt) 2019-04-10
EP1984018B1 (en) 2014-10-01
EP1984018A2 (en) 2008-10-29
CN101431960A (zh) 2009-05-13
WO2007084737A2 (en) 2007-07-26
IL192740A (en) 2017-11-30
SI2666476T1 (sl) 2019-04-30
US20090130079A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
MX349749B (es) Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico.
MX2022005303A (es) Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurologicas.
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
WO2010059253A3 (en) Methods and compositions for localized agent delivery
MX348420B (es) Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
WO2009073050A3 (en) Use of curcumin to block brain tumor formation in vivo
MX2007010996A (es) Nuevas composiciones de liposomas.
NZ600858A (en) Suture line administration technique using botulinum toxins
BRPI0916356A2 (es)
WO2010006219A3 (en) Use of scaffold comprising fibrin for delivery of stem cells
HK1209633A1 (en) Compositions and methods for treating diabetes
WO2006116353A3 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
MX2011006347A (es) Conjugados de oligosacaridos-proteinas.
WO2009134866A3 (en) Cell membrane engineering
WO2009135178A3 (en) Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
WO2009155439A3 (en) Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2061456A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
WO2007048019A3 (en) Delivery system for diagnostic and therapeutic agents
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008089339A3 (en) Oligosaccharide conjugates for cellular targeting